参考文献/References:
[1]LOUIS DN, PERRY A, WESSELING P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary [J]. Neuro Oncol, 2021, 23(8): 1231-1251.
[2]JIANG T, NAM DH, RAM Z, et al. Clinical practice guide-lines for the management of adult diffuse gliomas [J]. Cancer Lett, 2021, 499: 60-72.
[3]AMMENDOLA S, BROGGI G, BARRESI V. IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification [J]. Histol Histopathol, 2023, 38(7): 739-753.
[4]DANG L, WHITE DW, GROSS S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate [J]. Nature, 2009, 462(7274): 739-744.
[5]DANG L, YEN K, ATTAR EC. IDH mutations in cancer and progress toward development of targeted therapeutics [J]. Ann Oncol, 2016, 27(4): 599-608.
[6]CHEN S, ZHU H, JIN M, et al. Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies [J]. Cancer Med, 2022, 11(22): 4122-4133.
[7]TESILEANU CMS, VALLENTGORD WR, SANSON M, et al. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations [J]. Acta Neuropathol, 2021, 141(6): 945-957.
[8]HILLE F, RICHTER H, WONG SP, et al. The biology of CRISPR-cas: backward and forward [J]. Cell, 2018, 172(6): 1239-1259.
[9]BARRANGOU R, FREMAUX C, DEVEAU H, et al. CRISPR provides acquired resistance against viruses in prokaryotes [J]. Science, 2007, 315(5819): 1709-1712.
[10]CARSTAM L, CORELL A, SMITS A, et al. WHO grade loses its prognostic value in molecularly defined diffuse lower-grade gliomas [J]. Front Oncol, 2021, 11: 803975.
[11]WIJNENGA MMJ, FRENCH PJ, DUBBINK HJ, et al. The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis [J]. Neuro Oncol, 2018, 20(1): 103-112.
[12]WANG P, LUO C, HONG PJ, et al. The role of surgery in idh-wild-type lower-grade gliomas: threshold at a high extent of resection should be pursued [J]. Neurosurgery, 2021, 88(6): 1136-1144.
[13]MOLINARO AM, HERVEY-JUMPER S, MORSHED RA, et al. Association of maximal extent of resection of contrast-enhanced and non-contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed glioblastoma [J]. JAMA Oncol, 2020, 6(4): 495-503.
[14]NEFF C, CIOFFI G, WAITE K, et al. Molecular marker testing and reporting completeness for adult-type diffuse gliomas in the United States [J]. Neurooncol Pract, 2023, 10(1): 24-33.
[15]KOH J, CHO H, KIM H, et al. IDH2 mutation in gliomas including novel mutation [J]. Neuropathology, 2015, 35(3): 236-244.
[16]GUARNACCIA M, GUARNACCIA L, LA COGNATA V, et al. A targeted next-generation sequencing panel to genotype gliomas [J]. Life (Basel), 2022, 12(7): 956.
[17]CHEN JS, MA E, HARRINGTON LB, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity [J]. Science, 2018, 360（6387）: 436-439.
[18]YAN WX, HUNNEWELL P, ALFONSE LE, et al. Functionally diverse type V CRISPR-Cas systems [J]. Science, 2019, 363(6422): 88-91.
[19]ZETSCHE B, GOOTENBERG JS, ABUDAYYEH OO, et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system [J]. Cell, 2015, 163(3): 759-71.
[20]LIANG Y, LIN H, ZOU L, et al. CRISPR-Cas12a-based detection for the major SARS-CoV-2 variants of concern [J]. Microbiol Spectr, 2021, 9(3): e0101721.
[21]MAYURAMART O, NIMSAMER P, RATTANABURI S, et al. Detection of severe acute respiratory syndrome coro-navirus 2 and influenza viruses based on CRISPR-Cas12a [J]. Exp Biol Med (Maywood), 2021, 246(4): 400-405.
[22]QIAN W, HUANG J, WANG T, et al. Visual detection of human metapneumovirus using CRISPR-Cas12a diagnostics [J]. Virus Res, 2021, 305: 198568.
[23]KELLY R, ALBERT M, DE LADURANTAYE M, et al. RNA and DNA integrity remain stable in frozen tissue after long-term storage at cryogenic temperatures: a report from the ontario tumour bank [J]. Biopreserv Biobank, 2019, 17(4): 282-287.